Atrial Fibrillation Guideline Update: Part I

CEimpact Podcast

Atrial fibrillation is the most common clinical arrhythmia. The newest guidelines have significant changes in diagnosis, assessment, and treatment. Join host, Geoff Wall, as he evaluates the first half of the guidelines in this two-part episode.
The GameChanger
Different stratifying types of atrial fibrillation no longer exist. Additionally, left atrial occlusive devices are now recommended as first-line therapy for the prevention of stroke, though anticoagulants are the treatment of choice.
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2023 Nov 23:S0735-1097(23)06465-3. doi: 10.1016/j.jacc.2023.08.017. Epub ahead of print. PMID: 38043043.
https://www.jacc.org/doi/10.1016/j.jacc.2023.08.017

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe new definitions of atrial fibrillation and risk factors for stroke
2. Discuss mechanical prevention of stroke in high risk patients
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-401-H01-P
Initial release date: 12/25/2023
Expiration date: 12/25/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Capitole

1. Atrial Fibrillation Guideline Update: Part I (00:00:00)

2. Clinical Guidelines for Atrial Fibrillation (00:00:08)

3. Guidelines for Anticoagulation and DOACs (00:11:45)

4. Use of Anti-Platelet Agents and DOAX (00:25:25)